Transforming Bioactive Proteins into Therapeutic Products
Now into its fourth decade, PEGylation has come a long way from the original
random conjugation chemistries that resulted in mixtures of PEG positional
isomers with subsequent mixtures of biological activities. Continued innovation
now means it is possible to more precisely control the site of PEGylation,
leading to more homogeneous medicines with predictable behaviour.
By Anthony Godwin at PolyTherics Ltd (September 2009)
Keywords: bioactive proteins, therapeutic products, homogeneity, pharmacokinetics, protein formulation, biopharmaceuticals, genomics, proteomics